Wuxi, China, Jan. 27, 2026 — Park Ha Biological Technology Co., Ltd. (NASDAQ: BYAH) (the “Company”) announced today the pricing for a best-efforts follow-on public offering of 21,875,000 units (each a “Unit”) at US$0.112 per Unit.
Each Unit is comprised of one Class A ordinary share of the Company, with a par value of US$0.00002 per share (each, a “Class A Ordinary Share”), and one warrant to purchase one Class A Ordinary Share (or up to nine Class A Ordinary Shares under the zero exercise price option) (each, a “Warrant”). The exercise price for each Warrant is US$0.112 per Class A Ordinary Share, and the Warrants will be exercisable from the issuance date until the one-year anniversary of the issuance date.
The Company anticipates receiving total gross proceeds of US$2.45 million from the offering, prior to the deduction of placement agent commissions and other estimated expenses payable by the Company, and not including the exercise of any Warrants offered.
The offering is anticipated to close on or around January 28, 2026, contingent upon the fulfillment of customary closing conditions. The Company plans to allocate the net proceeds from this offering toward expanding its directly operated stores in China, with the exact distribution of net proceeds across markets determined by market conditions.
D. Boral Capital LLC is serving as the Sole Placement Agent for the offering.
The securities mentioned above are being offered by the Company under a registration statement on Form F-1 (File No. 333-290410), as amended, which was previously filed and declared effective by the U.S. Securities and Exchange Commission (the “SEC”). This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor will there be any sale of these securities in any state or jurisdiction where such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction. The offering will be made solely by means of a prospectus that forms part of the effective registration statement. A final prospectus related to the offering will be filed with the SEC and will be accessible on the SEC’s website at . Electronic copies of the final prospectus, when available, can be obtained from D. Boral Capital LLC at , or by calling +1 (212) 970-5150.
About Park Ha Biological Technology Co., Ltd.
Founded in 2016, Park Ha Biological Technology Co., Ltd. focuses on developing its private skincare label, selling skincare products directly, and promoting franchise alliances under its proprietary brand “Park Ha,” with a dedication to delivering affordable solutions for skin issues and enhancing the confidence of women seeking skin treatment. As of April 30, 2025, the Company operates three directly managed stores and has 39 franchisees, with 38 operating under the “Park Ha” store name and one under “Geni,” all located in China. As a value-added service for its products, the Company provides a “light beauty experience,” a complimentary quick after-sales beauty service available in both directly operated and franchise stores. For more information, please visit the Company’s website: /.
Forward-Looking Statements
Some statements in this announcement are forward-looking statements. These forward-looking statements entail known and unknown risks and uncertainties and are based on the Company’s current expectations and projections regarding future events that the Company believes could impact its financial condition, operational results, business strategy, and financial requirements. Investors can identify many (though not all) of these statements by terms such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may,” or similar expressions in this announcement. The Company assumes no duty to update or revise publicly any forward-looking statements to reflect events or circumstances that occur subsequently, or changes in its expectations, except as required by law. While the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot guarantee that such expectations will prove to be correct, and the Company advises investors that actual results may vary significantly from projected results and urges investors to consider other factors that may influence its future results in the Company’s registration statement and other SEC filings.
For more information, please contact:
D. Boral Capital LLC
590 Madison Avenue, 39th Floor
New York, NY 10022
Main Phone: +1 (212) 970-5150
Park Ha Biological Technology Co., Ltd.
901, Building C
Phase 2, Wuxi International Life Science Innovation Campus
196 Jinghui East Road
Xinwu District, Wuxi, Jiangsu Province
People’s Republic of China 214000
